Estrella Immunopharma Highlights ARTEMIS T-Cell Therapy Data for Leukemia Treatment at ASH 2026
Estrella Immunopharma, a clinical-stage biopharmaceutical company, has highlighted preclinical findings for its ARTEMIS T-cell therapy platform, demonstrating deep and durable leukemia responses and superior extramedullary disease clearance compared to conventional CAR-T cells. These findings, detailed in an abstract accepted for presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2026, support the potential of Eureka Therapeutics' ARTEMIS chimeric γδ antibody-TCR (AbTCR) T cells. The research focused on overcoming the challenge of extramedullary leukemia, where malignant cells persist outside the bone marrow and contribute to disease progression and relapse. In preclinical models of acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL), ARTEMIS T cells achieved approximately 10,000-fold reductions in leukemia burden, complete regression of extramedullary AML lesions, and faster, deeper responses than conventional CAR-T cells.